ARCHIVES

Beta Blockers Negate Harmful Recurrence Risks of ACE Inhibitors

This article is from The Cancer Letter archive.

Vol. 34 No. 4 | April 29, 2011

Download PDF Visit The Full Archive

Related Articles

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

June 24, 2011

Panel To Take Up Issues In Grant/Peer Review System, Consider NCAB Membership Requirements

December 11, 1981

NCI To Invite Unaffiliated Oncologists To Enroll Patients On Phase III Trials

May 10, 2002

NCI To Require Reports On Adverse Drug Reactions From Trials

June 10, 1994

Multiple Studies Show Benefit of CTL019, A Personalized Therapy, in CLL and ALL

December 27, 2013

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

May 31, 2013